Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide for CMV Prophylaxis in Haploidentical HSCT
NCT07709013Phase 2Recruiting
- Sponsor
- Tata Memorial Centre
- Start
- Oct 2024
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of leflunomide in cytomegalovirus infection (CMV), sponsored by Tata Memorial Centre. Primary endpoint: Clinically significant cytomegalovirus (CMV) infection at 180 days. Started Oct 2024; status: recruiting.
02
Drugs
leflunomide
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT07709013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07709013.